Sermorelin vs Tesamorelin: both are GHRH analogues, but tesamorelin has a longer half-life (~26 min vs ~10 min) and is the only GHRH analogue with FDA approval (for HIV-associated lipodystrophy).
Half-Life and GH Pulse Pattern
Sermorelin: ~10–20 minute half-life, sharp GH pulse, requires multiple daily injections. Tesamorelin: ~26 minute half-life, more sustained GH pulse, once-daily dosing is standard. Tesamorelin produces more consistent IGF-1 elevation.
Clinical Evidence Comparison
Tesamorelin: FDA-approved, multiple Phase 3 trials, validated IGF-1 elevation of 100–150 ng/mL above baseline. Sermorelin: extensive research history but no FDA approval for GH deficiency; clinical data is less robust than tesamorelin.
Cost and Availability
Sermorelin is significantly less expensive than tesamorelin and more widely available from research suppliers. Tesamorelin is preferred when clinical evidence quality is a priority; sermorelin when cost-effectiveness is the primary consideration.